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Abstract 
 
Multiple sclerosis is characterised at the gross pathological level by the presence of widespread 
focal demyelinating lesions of the myelin-rich white matter. However, in recent years it has become 
clear that grey matter is not spared, even during the earliest phases of the disease. Furthermore, grey 
matter damage has been suggested to have an important role both in physical and cognitive 
disability. Grey matter pathology involves both inflammatory and neurodegenerative mechanisms, 
but the relationship between the two is unclear. This review will summarize and highlight important 
histological, immunological, and neuroimaging results from this rapidly expanding field and will 
address the most recent hypotheses on the pathogenesis of grey matter damage. 
 
 
Introduction  
 
 Multiple Sclerosis is a chronic immune-mediated demyelinating disease of the central 
nervous system (CNS). Its aetiology has been suggested to involve both a complex genetic 
background with multiple susceptibility genes and several environmental factors1-4. Multiple 
sclerosis is characterized pathologically by inflammation, demyelination with partial restoration of 
myelin, axonal and neuronal damage and glial scarring5,6. The pathogenetic mechanisms leading to 
these abnormalities are largely unclear.  
As disseminated focal demyelinating lesions in the white matter are the classical hallmark of 
multiple sclerosis, the disease has long been considered a ‘typical white matter disease’. 
Nevertheless, early histological reports noted that grey matter is also affected and that grey matter 
damage and cell loss may underlie some of the permanent neurological dysfunction. In 1916, in a 
comprehensive overview of the histology of disseminated sclerosis, James W. Dawson wrote: “(…) 
when an area [of demyelination] is confined to the cortex, the changes are, as a rule, not nearly so 
marked (…).”7, referring to the striking lack of glial proliferation and cellular paucity (an indicator 
that inflammation was absent) in grey matter lesions. Dawson also wondered: “Is then, the process 
that attacks the cortex different in its nature and origin from that which affects the rest of the 
central nervous system?” This tantalizing question remains highly relevant today.  
There was little post-mortem tissue research investigating grey matter pathology in multiple 
sclerosis until 1962, when the interest in grey matter lesions in multiple sclerosis was rekindled by a 
seminal histopathology study8 that reported that 26% of multiple sclerosis lesions were located in or 
around the cortical and subcortical grey matter. As would later be apparent, this was a gross 
underestimation of actual grey matter damage. It was another four decades before advances in 
imaging techniques9,10, supported by immunohistochemical observations and animal models, 
renewed the interest in grey matter pathology in multiple sclerosis and began to reveal its high 
prevalence and to uncover the detailed cellular pathology of grey matter demyelination11-13.  
 However, despite the extensive pathological characterisation and the imaging evidence of 
grey matter lesions (Figure 1), the causes of grey matter damage and its relationship to white matter 
lesions remain unclear. This review aims to provide an overview of existing theories about grey 
matter damage in multiple sclerosis, answering, from a histological, immunological, and 
neuroimaging point of view, some of the most pertinent questions about its pathogenesis. 
  
Are white and grey matter damage linked?  
 
Since the first demonstration that the cortex is not spared by multiple sclerosis, the question of 
whether cortical tissue damage is secondary to white matter pathology — that is, whether it occurs 
via retrograde degeneration — or is a primary pathological process has remained unresolved.  
Grey matter lesions are usually characterised by a relative lack of parenchymal lymphocyte 
infiltration, deposition of antibody and complement proteins, and blood brain barrier disruption 
when compared to white matter lesions12,14,15. In post mortem samples taken from individuals in the 
advanced stages of multiple sclerosis, high numbers of immune cells were only detected in Type I 
grey matter lesions (Figure 1A): all other grey matter lesions were categorized as relatively “non-
inflammatory”11-13. Moreover, according to post-mortem studies, neuronal loss occurs within both 
grey matter demyelinated lesions and normal appearing grey matter12,16,17, suggesting that neuronal 
loss might occur independently from grey matter demyelination. 
 These findings imply that grey matter might be damaged either from local inflammation that 
has occurred earlier within the grey matter or as a consequence of white matter lesions that are 
themselves caused by inflammation. 
 
Evidence that links grey and white matter damage  
 
In line with the idea that white matter damage may drive grey matter damage, several MRI 
studies have reported a significant correlation between white matter damage and grey matter 
atrophy in conditions other than multiple sclerosis18. For example, advanced post-processing 
analyses showed a reduction of cortical grey matter volume and thinning of the primary motor 
cortex in patients with spinal cord injury, suggesting that distant axonal transection can lead to 
significant cortical atrophy via retrograde degeneration18.  
It has been suggested that the characteristic pattern of white matter pathology in multiple 
sclerosis could lead to selective retrograde injury to frontal, temporal and motor cortical areas, 
which would explain some, but not all, of the post mortem patterns of grey matter damage that have 
been observed19. Indeed, the cortico-spinal tract, which contains fibre connections to the precentral 
gyrus, and the frontal periventricular white matter, which consists of efferent and afferent fibres to 
frontal and superior temporal lobes, are common sites of white matter lesions in multiple 
sclerosis20. Moreover, axonal damage in active white matter lesions (i.e. gadolinium-enhanced on 
contrast MRI) could lead indirectly to anterograde and retrograde degeneration (Figure 2) of axons 
running within the thalamus and basal ganglia. Axon loss might also contribute to demyelination 
and/or Wallerian degeneration by reducing local metabolic activity21,22. A correlation 
between white matter lesion load and thalamic atrophy was found in patients with clinically isolated 
syndrome23 and early relapsing remitting multiple sclerosis (RRMS)24. More generally, the 
assumption that white matter lesions and grey matter atrophy are linked is supported by several 
cross-sectional MRI studies showing significant correlations between the total grey matter volume 
and the total volume of white matter T1- and T2-weighted lesions25-28. Even when a more sensitive 
regional analysis was performed, a correlation between regional cortical grey matter loss and white 
matter lesion volume in the corresponding or adjacent lobes in progressive multiple sclerosis 
patients was observed29, although the location and extent of grey matter lesions were not studied. 
Finally, several longitudinal MRI studies30-32 point to an association between increasing white 
matter lesion volumes and grey matter volume loss in the frontal and parietal cortex of patients with 
RRMS. In addition, white matter lesion volume correlated with ventricular enlargement32, focal 
white matter damage in the optic radiations (see figure 3A, 3B, 3C) and upstream grey matter 
atrophy of the lateral geniculate nucleus and visual cortex in patients with RRMS33.  
 
Evidence for independent grey matter damage  
 An alternative but equally important theory suggests that white matter and grey matter 
demyelination are two, at least partly, independent phenomena and that neuronal loss is not caused 
by white matter abnormalities per se. Proponents of this theory suggest that retrograde changes as a 
result of focal white matter lesions do not satisfactorily explain the extent of the cellular pathology 
and diffuse nature of grey matter changes (Figure 3D, 3E, 3F compared to 3G, 3H, 3I).  
Extensive pathological and imaging evidence supports this argument. For example, several recent 
studies of grey and white matter demyelination in different regions of the CNS found that the extent 
of cortical demyelination is greater than that found in white matter34 and that, 
although cortical demyelination sometimes occurred together with demyelination in the adjacent 
white matter (leukocortical lesions), in most instances, the cortex was affected independently from 
white matter lesions35,36. Another study observed a gradient of neuronal loss in the precentral gyrus 
of MS cases that exhibited extensive subpial demyelination with the greatest loss in the outer 
cortical layers17. There was no relationship between this gradient and the white matter lesion 
volume or location, which argues strongly against an influence of white matter lesions on grey 
matter subpial pathology. On the contrary, it is likely that extensive primary neuronal loss in the 
cortical grey matter would lead to anterograde loss of axons in downstream white matter pathways, 
including the spinal cord.  
It has also been shown that extensive and complete subpial demyelination of individual gyri and 
sulci accompanied by the relative preservation of axons characterises many cases of secondary 
progressive multiple sclerosis (SPMS)12,37. This pattern of damage cannot be explained by axonal 
damage in white matter lesions, which would lead to more diffuse but incomplete decrease in 
myelin density due to the loss of individual myelin–axon units. Extensive subpial demyelination 
was also observed in single biopsies of very early RRMS38. In vivo imaging studies confirmed the 
presence of grey matter lesions during the earliest phases of the disease39 in patients with very low 
white matter lesion volume, and sometimes even in patients with radiologically isolated syndrome 
(before any clinical symptoms are present40), or preceding the occurrence of white matter lesions 
altogether41. However, it should be pointed out that even when using the most advanced 
technologies, most grey matter lesions (especially type 3 subpial lesions (figure 1C) escape 
identification by MRI, making it difficult to accurately correlate grey matter and white matter 
damage by this method42. 
Other radiological data suggested that diffuse grey matter atrophy is only partially related to 
the white matter damage visible by MRI. When brain atrophy was studied in early RRMS patients, 
for example, both grey and white matter atrophy were observed, but the correlation between the two 
was only moderate43. A 2-year follow-up of these patients revealed that fluctuations in 
inflammatory white matter lesions were related to volume changes in white matter rather than to 
grey matter loss44. Voxel-based morphometry and tract-based spatial statistical analyses were 
applied to assess regional grey matter and white matter damage in 36 RRMS and 25 sex- and age-
matched controls. As expected, this revealed significant differences between patients and controls. 
However, although several measures of white matter damage correlated with each other, none 
correlated with grey matter volume45. More recent imaging studies have found that the relationship 
between grey matter atrophy and white matter abnormalities was weaker in primary and secondary 
progressive disease than in RRMS suggesting that neurodegenerative processes in patients with 
progressive disease are even less related to white matter changes46. These findings could indicate 
that grey matter damage is either independent of white matter lesions or that white matter is 
affected in a way that is not detected by currently applied imaging techniques. 
Finally, grey matter lesion probability maps and regional analysis of grey matter atrophy 
revealed a specific topographical distribution of focal and diffuse damage47. Most grey matter 
lesions were found in the fronto-temporal lobes, with a particular prevalence in the motor regions. 
High probability of focal grey matter demyelination was observed in the hippocampus, deep grey 
matter and insula48,49, whereas a significant increase in the distribution of diffuse subpial 
demyelination was observed by means of 7T magnetic resonance in the anterior cingulate cortex50. 
Grey matter demyelination has also been observed in the limbic system and in specific cortical 
areas such as the mesial temporal lobe51. Nevertheless, the spatiotemporal topographical 
distribution of white matter lesions did not reveal any direct anatomical overlap between areas of 
significant grey matter volume reduction and significant focal white matter lesion volume 
increases52.  
 Does grey matter damage occur as result of or independently of white matter damage? As 
described above, evidence exists for both. There is little doubt that axonal damage can lead to 
retrograde loss of neurons. However, it does not explain the spectrum and extent of grey matter 
damage in multiple sclerosis, and several studies clearly suggest that the mechanisms of damage 
within white matter and grey matter may be, at least partly, independent. Furthermore, primary 
damage to cortical neurons could give rise to anterograde axonal loss, particularly in the spinal 
cord. 
 
Inflammatory grey matter damage  
 
 Although there is overall little information on the immune mechanisms that are active in the 
cortical layer in multiple sclerosis patients, several causes of inflammatory demyelination within the 
grey matter can be envisioned (Figure 4). These include the possible expression or relative 
overabundance of a target autoantigen for adaptive (T cell- and antibody-mediated) immune 
mechanisms53 or the involvement of a T cell with specificity for both a myelin- and neuronal 
antigen54. An alternative hypothesis suggests that the presence of inflammatory infiltrates in the 
meningeal space and/or in the adjacent perivascular spaces might lead to the release of cytotoxic 
inflammatory mediators into the grey matter 17,38,55. This could be caused by an infectious organism 
located in the adjacent meninges or by a chronic compartmentalised inflammatory response to self-
antigen(s). Several epidemiological studies have suggested that Epstein-Barr virus (EBV) is one of 
the strongest candidates for this infectious agent56-58 and EBV proteins and RNA have been 
detected in B-cells in the meninges and perivascular spaces of MS cases with extensive meningeal 
infiltrates and cortical demyelination59-61. It has been proposed that failure to control latent EBV 
infection in an immune privileged site, such as the subarachnoid space, could lead to recurrent 
intrathecal reactivation of EBV and tissue damage in the nearby grey matter62,63. However, a 
number of other studies have been unable to detect EBV in the brain or lesions of MS patients64,65 
and this remains a highly debated controversy66. The different results found in these studies are 
likely to be due to the different types of tissues and MS cases used, the variable preservation of 
meningeal tissues in the samples, and differences in the sensitivity of the techniques used to detect 
EBV infection67. Other viruses, such as Torque Teno virus, have also been hypothesised to play a 
role in the pathogenesis of MS, on the basis that they can infect the CNS68, are a target for 
cerebrospinal fluid (CSF)-infiltrating T cells isolated from multiple sclerosis patients69 and interact 
with EBV68,69. Furthermore, myco-like viruses that are closely related to Torque Teno virus have 
recently been isolated from cow milk and the brains of MS patients providing an interesting link to 
epidemiological findings on the consumption of cow milk and the geographical prevalence rates of 
MS70. Alternatively, cortical demyelination and neuronal loss could involve an infectious agent 
with primary tropism for oligodendrocytes and/or cortical neurons71, although no evidence exists 
yet for this possibility in multiple sclerosis.   
Other mechanisms that might target adaptive and/or innate immune responses to the grey 
matter include alterations specifically linked to the function and/or degeneration of neurons, 
astrocytes or oligodendrocytes, such as metabolic changes72, excitatory neurotransmitter release73, 
expression of post-translationally modified proteins and/or peptides74, changes in electrical activity 
and/or ion currents and cytokine and/or cytokine receptor expression75. 
 Although none of these possible reasons has yet been proven to be a cause of the 
topographical distribution of grey matter damage in multiple sclerosis, there are data in support of 
these ideas, and we therefore believe that they can at least serve as a working hypothesis and basis 
for further investigation.  
 
Role of parenchymal and perivascular lymphocytes 
 
A recent study demonstrated that the extent of lymphocyte infiltration in grey matter lesions 
depends on the disease stage: foamy macrophages, thought to be involved in ongoing 
demyelination, were found in grey matter active lesions of 66% of early RRMS patients at biopsy 38 
but were rarely found in grey matter lesions from SPMS patients37. The presence of perivascular 
CD8+ T cells was observed in 77% of intracortical lesions at biopsy with varying frequency 
depending on the location examined (with numbers decreasing from leucocortical regions to 
intracortical lesions and being lowest in subpial lesions12,38). Perivascular T- and B cell infiltrates 
have also been observed in both intracortical and sub-pial lesions in progressive multiple sclerosis 
cases55, particularly in subjects in whom progressive disease with signs of activate inflammation 
was present at death. The reasons for the heterogeneous distribution of CD8+ T cells in the cortex, 
their relatively higher frequency in leukocortical- and intracortical plaques in comparison to subpial 
ones and their localization in perivascular cuffs38 are at present not clear, and further studies are 
clearly needed. 
A wealth of immunological data suggests that CD4+ T cells are inducers and drivers of 
multiple sclerosis2. Key findings that support this notion are among others the strong genetic 
influence of the HLA-DR15 haplotype76,77, the increased frequency of myelin-specific CD4+ T 
cells with a proinflammatory phenotype in MS78,79, and their higher antigen avidity80. However, 
although CD4+ T cells are present in the inflamed meninges above sub-pial grey matter lesions17, 
little information is available concerning their presence within cortical grey matter lesions. This is 
surprising if one considers that HLA-class II molecules (including HLA-DR alleles) serve as 
recognition structures for CD4+ T cells and the HLA-DR15 haplotype is by far the most important 
genetic risk factor in multiple sclerosis76,77. In fact, a recent study suggested that HLA-DRB1*15 
status is associated with the extent of inflammation and demyelination in motor cortex at autopsy81, 
indirectly suggesting that CD4+ T cells (or an as yet unknown role of HLA-class II molecules) are 
involved in tissue inflammation in the grey matter.  
Despite the evidence for a role for CD4+ T cells in multiple sclerosis, CD8+ T cells are found at 
higher frequency than CD4+ T cells in the grey matter and brains of multiple sclerosis patients at 
autopsy 38,82, and are more frequently clonally expanded,83  i.e. these cells have proliferated locally 
in the brain. However, the local proliferation within the grey matter lesions themselves has not been 
examined yet, and CD4+ intracerebral T cells have generally been studied less well. CD8+ T cells 
are also thought to be more likely to directly damage neurons and other CNS cells than CD4+ T 
cells because HLA-class II molecules are expressed at very low levels and on a limited number of 
cells in the CNS, whereas HLA-class I molecules, which present antigen to CD8+ T cells, show 
broader expression in multiple sclerosis brain75. However, although HLA-class II molecules are not 
expressed by neurons, they are expressed by activated microglia and astrocytes. Proteins and 
peptides that are released from damaged neurons can be presented by these cells to CD4+ T cells84, 
although this process has not been examined yet in the grey matter of multiple sclerosis patients. 
Furthermore, HLA-class I molecule expression has been described in electrically silent neurons 
(those that are functionally compromised or damaged) and data from experimental systems suggests 
that the exposure of neurons to interferon-g (IFN-g) renders them immunological targets for CD8+ 
T cells75. In summary, the existing evidence suggests an involvement of both CD4+ and CD8+ T 
cells in cortical damage in multiple sclerosis albeit with different contributions, i.e. initiation and 
perpetuation by CD4+ T cells and effector mechanisms such as direct neuronal/axonal damage 
more likely by CD8+ T cells. 
Several mechanisms through which CD8+ and CD4+ T cells could damage neurons and 
oligodendrocytes have been proposed. These include antigen-specific and antigen-independent 
mechanisms as well as cell contact-dependent and -independent processes85. However, all of the 
major cytotoxic mechanisms that have been proposed – including the release of perforin86 or 
granzymes87, involvement of Fas/Fas-ligand88, cell lysis by TNF receptor-related apoptosis-
inducing ligand (TRAIL)89 and the induction by IFN-g of neuron-specific, calcium-permeable 
complexes between IFN-g-receptor and the glutamate receptor GluR190 – have been described 
mainly in experimental models. It is important to note that the ability to kill target cells by perforin- 
or Fas/Fas-ligand-mediated lysis, which is typically attributed only to CD8+ T cells, has also been 
shown for human CD4+ T cells91. Furthermore, an antigen-independent lysis mechanism that 
involves CD56 (or neural cell adhesion molecule, NCAM), which is expressed on natural killer 
cells and a subset of CD4+ T cells92, has been implicated in the lysis of oligodendrocytes93.   
 
Role of meningeal inflammatory infiltrates 
 In the last decade several neuropathology studies have shed light on the association between 
meningeal inflammation and pathology of the adjacent cerebral cortex, both in multiple sclerosis 
and in experimental autoimmune encephalomyelitis (EAE) models17,38,94-98. Aberrant tertiary 
lymphoid-like structures containing large aggregates of CD20+ B-cells17,37,94, which are hallmarks 
of several other chronic inflammatory diseases, were found in the inflamed meninges of a 
substantial proportion of SPMS cases that were examined post-mortem. Similar accumulations of 
B-cells have been reported in 40% of cortical biopsies from early RRMS cases, where they are 
associated with underlying subpial demyelination38. The SPMS cases exhibiting lymphoid-like 
immune cell aggregates were characterized by a high degree of inflammatory activity17,37,94,99. The 
study was carried out on a large number (123) of post-mortem MS cases with a wide range of ages 
at onset, progression and death and total disease duration in order to avoid selection bias37.  
However, an independent smaller study failed to find such lymphoid structures100. As has 
previously been discussed, this disparity may be a result of differences in the technical approaches 
used, such as different procedures of tissue processing, cutting and staining, and cohort choice.65,101. 
The presence of organised meningeal infiltrates occurred in the main in MS cases characterised by 
an earlier age at death and evidence of ongoing inflammatory activity and such cases are not always 
present in autopsy collections. In addition to the organised lymphoid-like structures that have been 
reported, extensive diffuse meningeal infiltrates have been detected at autopsy,100,102,103 which may 
explain the widespread nature of subpial demyelination. Subpial demyelination and cortical atrophy 
are more pronounced within deep invaginations of the cortex16,17,35, suggesting that regional 
differences in CSF flow and/or stasis may result in a shielded niche (or microenvironment) for the 
persistence of lymphoid-like structures within cerebral sulci. It can be speculated that this may 
sustain a local immune response – particularly enriched in CD20+ B lymphocytes and plasmablasts, 
but also comprising CD4+ and CD8+ T cells and macrophages– that chronically generates 
inflammatory, cytotoxic and possibly myelinotoxic mediators that, by circulating within the CSF, 
may diffuse freely throughout the subarachnoid space. These mediators might cross the pial 
membrane towards the adjacent grey matter and specifically mediate diffuse and focal subpial grey 
matter injury in multiple sclerosis. The release and circulation of specific, but still as yet unknown 
factors, in the CSF bathing the cerebral cortex could explain the fact that subpial cortical 
demyelination is one of the most specific features of MS pathology104. Among these factors tumour 
necrosis factor (TNF) and IFN-γ, whose expression was found significantly increased both in the 
meninges and CSF samples from post-mortem SPMS cases with higher levels of meningeal 
inflammation and cortical damage99, may play a fundamental role in mediating subpial pathology 
directly or indirectly, by regulating microglia activity. This hypothesis is corroborated by the 
finding that the subset of SPMS patients with higher levels of inflammation and frequency of 
immune cell infiltrates in the meninges had a higher subpial grey matter lesion volume, a higher 
degree of neuronal, astrocyte and oligodendrocyte loss and increased microglial activation17,37, the 
severity of which followed a gradient from the external towards the innermost cortical layers.  
Interestingly, the subpopulation of SPMS cases with higher levels of meningeal inflammation and 
grey matter damage were characterised clinically by a more rapidly progressive disease 
course17,37,94,105, although it should be noted that this population of patients clearly represent the 
more aggressive end of the spectrum of heterogeneous presentations. The link between cortical 
pathology and a rapidly progressive disease course has also been described in a large proportion of 
multiple sclerosis cases using non-conventional imaging techniques39,105. These results support the 
idea that increased grey matter pathology, alone or in addition to white matter pathology, may be 
associated with a more rapid and aggressive disease course from early phases of the disease and that 
meningeal inflammation may in part be responsible for this increased pathology.  
The specific link between meningeal inflammation and severity of grey matter pathology and 
rapidly progressive disease course is further supported by studies of the spinal cord of post-mortem 
cases with secondary progressive multiple sclerosis106, where the levels of both meningeal T cells 
and activated parenchymal microglia were associated with increased diffuse axonal loss. 
Furthermore the recent examination of a large number of brain biopsies from patients with recently 
diagnosed multiple sclerosis38 has indeed revealed that cortical lesions occur early in the disease and 
are highly inflammatory and associated with both focal perivascular and diffuse meningeal 
inflammation.  The reported association between meningeal inflammation and immune infiltrates in 
chronic subpial lesions, either in brain biopsies from patients with early multiple sclerosis38 or in 
post-mortem SPMS cases with more aggressive grey matter pathology94, indicate that both 
meningeal and intraparenchymal grey matter inflammation may play a role in disease pathogenesis, 
either by causing cortical damage at the beginning of the disease and/or by exacerbating grey matter 
pathology as disease progresses 
 
Role of microglia 
Microglia are innate immune cells that are resident in the CNS and are considered to be the 
dominant effector cell population in cortical grey matter injury12. Elongated microglia that are 
oriented perpendicularly to the pial surface and are closely apposed to apical dendrites and axons, 
together with activated stellate microglia that extend processes to neuronal perikarya, dendrites and 
axons, are observed in active and chronic grey matter lesions107. The number of activated microglia 
and the degree of activation have been shown to correlate with the density of transected neurites in 
grey matter lesions12, suggesting that dendrites and axons are vulnerable to microglial activation107. 
Microglial activation could also be a consequence of neuronal and axonal damage and thus a sign of 
prior injury108. However, in post-mortem brain tissue, it has been shown that the number of 
microglia in cortical lesions also correlates with the degree of meningeal immune cell infiltration37. 
Therefore, it is unclear whether microglia have a neuroprotective and/or detrimental role within the 
cortex in multiple sclerosis or what the sequence of events is.  
In the mature brain microglia typically exist in a resting state and continually survey the 
microenvironment with their motile processes and protrusions109. Blood brain barrier disruption, 
brain injury or immunological stimuli provoke immediate and focal activation of microglia110. 
Depending on the circumstances of activation, microglia may differentiate into a type 1 phenotype, 
which can be proinflammatory and detrimental, or a type 2 phenotype, which is 
immunomodulatory, supports survival and provides an anti-oxidant defence111. However, the 
phenotype of activated microglia in cortical multiple sclerosis lesions has yet to be determined. In 
order for microglia to remain in a chronic state of activation in the multiple sclerosis cortex, there 
would need to be a chronic stimulus. It can be hypothesised that the presence of a chronically 
inflammatory milieu in the subarachnoid99 and perivascular spaces61 might represent such a 
stimulus. Other stimuli that promote microglial over-activation and dysregulation include 
environmental toxins and neuronal death or damage. However, the conditions that determine 
whether microglial activation is detrimental or beneficial to neuronal survival are currently poorly 
understood in multiple sclerosis.  
Nevertheless, it is becoming more widely accepted that, whereas microglial activation is 
necessary and crucial for host defence and neuronal survival, their over-activation may be 
deleterious to neurons and oligodendrocytes112. In postmortem homogenates of demyelinated and 
non-demyelinated cerebral cortical regions from multiple sclerosis cases, grey matter demyelination 
was found to be associated with increased activity of myeloperoxidase, which is expressed by a 
CD68-positive subset of activated microglia found in active GM demyelination toward the edge of 
the lesions but not by microglia in adjacent non-demyelinated cortex113. Moreover, the presence of 
activated microglia in grey matter lesions in multiple sclerosis patients has been correlated with 
focal loss of the glutamate transporters, EAAT1 and EAAT2, and synaptophysin 
immunostaining114, suggesting that activated microglia may also perturb astrocyte function and 
glutamate metabolism. Alterations in the mechanisms of glutamate reuptake found in grey matter 
lesions in the presence of activated microglia could be associated with signs of neuronal and 
synaptic damage suggestive of excitotoxicity114 (see below). Furthermore, an increase in microglial 
activity together with neuronal and axonal loss has been found in subpial cortex of SPMS patients 
with increased diffuse and organised meningeal inflammation37,94. Increases in the numbers of 
activated CD68+ microglia have also been observed in active and/or chronic cortical lesions of 
primary progressive multiple sclerosis patients at autopsy103, and rims of activated microglia are 
found at the border of grey matter lesions in a large fraction of multiple sclerosis patients with 
extensive subpial demyelination115. These patients were younger at time of death than patients 
without grey matter lesions or patients without rims of activated microglia in grey matter lesions100.  
 
Non-inflammatory neurodegeneration?  
 A recent theory points to inconsistencies in the inflammatory model described above 
and suggests instead a degenerative model as the primary cause of the disease.  
This model proposes that a primary ‘cytodegeneration’, initially focused on 
oligodendrocytes and/or neurons, begins years before any clinical symptoms. The autoimmune 
inflammatory reaction that is later observed would depend on the host’s predilection to react to the 
antigens released as a consequence of the (neuro)degeneration. This hypothesis arose as a result of 
inconsistencies in the literature, including observations of early myelin protein degradation before 
the prototypical adaptive immune response and the inability to stop disease progression using potent 
anti-inflammatory drugs116-118. 
However, although this hypothesis seems plausible, other interpretations are more likely: for 
example, adaptive immune processes that initiate white matter and grey matter damage may later – 
when demyelination and indirect injury to axons as well as direct axonal transections have reached 
a critical level – lead to on-going neurodegeneration that progresses independently of new 
inflammation. Alternatively, the efficacy of current immunomodulatory therapies may decrease as 
the immune response that drives multiple sclerosis pathology becomes increasingly 
compartmentalised within the CNS or CSF. According to this hypothesis, on-going inflammation 
would require less infiltration of cells from the peripheral immune system and therefore might not 
respond to systemically delivered therapies that primarily act as immunomodulatory in the 
peripheral immune system. It is likely, as has been suggested previously116, that multiple sclerosis 
involves both ‘inside-out’ and ‘outside-in’ disease mechanisms, jointly contributing to its variable 
course. However, large genome-wide association studies support a primary role of immune system 
alterations, since the vast majority of the more than 100 common genetic variants119, that have 
identified so far are immune-related.  
 
 
Conclusions and Perspectives  
The evidence reviewed above suggests that damage to the grey matter in multiple sclerosis 
proceeds in a manner that is in part independent of white matter damage, although there is clearly 
some degree of relationship between them (Box 1). This relative independence is illustrated by the 
fact that some cases of multiple sclerosis exhibit predominantly grey matter pathology with little 
white matter involvement and vice versa. Neuronal degeneration inevitably follows axonal 
transection in white matter lesions and will lead to a variable and dispersed loss of neurons in grey 
matter areas related to the anatomical location of the white matter lesions. Neuronal loss in the grey 
matter, as a result of inflammatory processes or more intrinsic mechanisms of degeneration (i.e. a 
local energy deficit due to mitochondrial dysfunction, Box 2), will also lead to axon loss and 
degeneration of downstream neurons. Whether grey matter damage may, at some point in the 
disease, proceed due to a primary degenerative process independent of inflammation and 
independent of white matter damage remains to be resolved: at present there is no evidence of a 
primary trigger similar to that seen in other neurodegenerative conditions. Evidence exists for a role 
of inflammatory processes, both innate in the parenchyma and adaptive in the meninges and 
perivascular spaces, alongside a role for degenerative processes involving mitochondrial 
dysfunction and energy deficits. However, these different processes have yet to be fully linked. 
Studies of the very early stages of the disease are required to clarify whether inflammation and/or 
immune mechanisms or neurodegeneration is the primary cause of the disease, but it is already clear 
that at some point both mechanisms are simultaneously active in grey matter and white matter in 
multiple sclerosis. To complicate matters further, the relationship between white and grey matter 
damage may differ across brain regions, disease phases and multiple sclerosis phenotypes. 
Additional longitudinal studies that focus on the very early stages of the disease, when either the 
white matter or the grey matter are almost intact, are required to clarify the relationship between 
white and grey matter damage. Since such studies are unlikely to be possible using post-mortem or 
biopsy tissue, the most promising approaches will be combinations of ever more sophisticated 
imaging methods such as MRI, spectroscopy and PET imaging with immunological, proteomics 
and metabolomics methods using CSF.  
In the light of accumulating evidence that multiple sclerosis patients with similar white 
matter lesion volumes undergo a more severe clinical course in presence of higher and more diffuse 
grey matter lesion volumes and atrophy already from the early disease phases, it may be suggested 
that cortical pathology has a key role in determining the rate of disability progression in multiple 
sclerosis. As with other progressive neurodegenerative conditions, it is likely that the accumulation 
of disability is directly related to increasing loss of vital neuronal populations and the rate at which 
they are lost and their locations determine the relative rate of disease progression. However, unlike 
other neurodegenerative conditions, the loss of neurons and axons is much more diffuse, which is 
reflected in the heterogeneous decline in diverse motor, sensory and cognitive function. Knowledge 
of the mechanisms underlying grey matter damage and identification of measures of disease 
progression associated with cortical pathology could help identify prognostic biomarkers and 
individualized therapies with increased efficacy for patients with a predisposition to develop more 
severe cortical pathology and associated clinical deterioration. Whether this predisposition is linked 
to genetic, environmental or other factors and is common to white matter immunopathogenesis is 
still unknown and highlights the need for more detailed study. Despite the unknowns, from a 
therapeutic point of view, a combination of immunomodulatory and neuroprotective strategies 
appears most promising to limit grey matter degeneration and development of long-term disability. 
 
BOX 1: Possible mechanisms underlying grey matter damage  
 
Adaptive immunity and /or autoimmune mechanisms 
 
a) Auto-antigens  
 
The over-expression of specific auto-antigens, epitope spreading to antigens that are more 
abundantly expressed in the grey matter, post-translational modifications of molecules in the 
grey matter, or molecular mimicry between myelin- and neuronal antigens has been 
hypothesised to activate T cells (preferentially CD8+ cytotoxic T cells rather than o CD4+ T 
helper cells).  
 
b) Infectious agents and compartmentalised immune responses  
 
It is hypothesised that an infectious organism located in the adjacent meninges or an 
infectious agent with primary tropism for cortical neurons and/or oligodendrocytes may 
result in formation of aberrant tertiary lymphoid-like structures within the meninges or the 
cortical layer and may induce a chronic compartmentalised inflammatory response against 
neurons or oligodendrocytes that is characterised by the presence of CD4+ and CD8+ T-
cells and CD20+ B-cells and plasmablasts.  
 
CNS innate inflammatory mechanisms 
 
a) Chronic Microglial Activation  
 
The presence of a chronic inflammation in the subarachnoid and perivascular spaces, 
environmental factors such as toxins, or neuronal damage or death, might cause an abnormal 
and chronic microglial over-activation that can be directly harmful to neurons and may also 
lead to a dysregulation of astrocyte functions and glutamate metabolism resulting in further 
neuronal and synaptic damage.  
 
Non-inflammatory neurodegenerative mechanisms 
 
a) Primary neurodegeneration  
 
A primary neurodegenerative event involving neurons, astrocytes or oligodendrocytes that 
may be caused or worsened by mitochondrial injury and metabolic compromise may explain 
the substantial neuronal injury with relatively minor parenchymal inflammation, microglial 
activation and associated meningeal inflammation, which are usually observed in multiple 
sclerosis. 
 
a) Retrograde degeneration due to white matter damage  
 
Reduction of cortical grey matter volume and thinning may be the consequence of white 
matter pathology via retrograde degeneration especially in the more advanced disease phase, 
thus explaining the significant neuronal loss observed even in the non-demyelinated cortex. 
 
BOX 2: Role of mitochondrial injury in grey matter damage 
 
Mitochondrial injury can be found in lesions characterized by all of the typical pathological features 
of multiple sclerosis including inflammation, demyelination, oligodendrocyte apoptosis, and axon 
degeneration119. A role for inflammation in mitochondrial dysfunction is suggested by post-mortem 
studies showing that reactive oxygen species (ROS) produced by activated microglia and 
macrophages can induce mitochondrial dysfunction not only in the white matter120, but also in the 
grey matter lesions104. Several lines of evidence have led to the hypothesis that mitochondrial injury 
is a primary phenomenon in multiple sclerosis121.  
a. Respiratory-chain deficient neurons have been identified in normal-appearing brain 
tissue 122.  
b. Respiratory-deficient neurons with multiple deletions in mitochondrial DNA are 
distributed diffusely in the cortex of MS patients122.  
c. Focal intra-axonal mitochondrial pathology is the earliest sign of damage in a mouse 
model of MS 123.  
d. Abnormal mitochondrial gene expression and impaired activities of mitochondrial 
respiratory chain complexes I and III, which can be found in demyelinated cortex 
samples of progressive MS patients124, may result in mitochondrial dysfunction and 
a state of impaired energy production.  
e. A characteristic hypoxia-like injury caused by mitochondrial impairment might be 
involved in neurodegeneration in MS lesions125126.  
Irrespective of the initial event, the presence of a local energy deficit in grey matter may induce a 
vicious cycle that leads to increased mitochondrial production ROS and further deletions of 
mitochondrial DNA127. Energy-deficient neurons may be more prone to inflammatory insult, which 
induces increased energy demand in the presence of a reduced energy supply128. Although the 
precise causes of neuronal respiratory deficiency in MS are yet unclear, the neuronal energy deficit 
is crucial for inducing axonal swelling and subsequent neuronal death, especially when it occurs as 
a consequence of inflammation, as is the case in grey matter regions in multiple sclerosis patients. 
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Suggested Glossary Terms 
 
 
Magnetic resonance imaging (MRI): A non-invasive method used to obtain images of living tissue. It uses 
radio-frequency pulses and magnetic field gradients; the principle of nuclear magnetic resonance is used to 
reconstruct images of tissue characteristics (for example, proton density or water diffusion parameters). 
 
Complement: A set of plasma proteins that attack extracellular pathogens. The pathogen becomes coated 
with complement proteins that facilitate pathogen removal by phagocytes 
 
Wallerian degeneration: The degeneration of an axon distal to a site of injury, which begins to occur about 
1.5 days after a lesion.  
 
Clinically isolated syndrome (CIS): patient having just the first clinical episode suggestive of a inflammatory 
demyelinating disease of the central nervous system  
 
Relapsing remitting multiple sclerosis (RRMS): early phase of Multiple Sclerosis characterized by several 
neurological episodes followed by complete or incomplete recovery 
 
Radiologically isolated syndrome: patients having the radiological evidence of an inflammatory 
demyelinating disease of the central nervous system but no signs or symptoms of such disease. 
 
Primary and secondary progressive disease: phases of multiple sclerosis characterized by a slow progression 
of disability without a well defined clinical relapse. They usually follow the relapsing remitting phase 
(secondary progressive phase) but they can also be the first phase of the disease (primary progressive 
multiple sclerosis) 
 
T cells: a lymphocyte type that is responsible for cell-mediated immune responses by providing help (e.g. 
cytokines) to other immune cells or by cytotoxicity, e.g. killing of a virus-infected cell. 
 
B cells: a lymphocyte type that expresses immunoglobulins as surface receptor or, when they are fully 
mature after antigenic stimulation, release antibodies, which are e.g. directed against a virus or bacteria. 
 
Natural killer cells: a white blood cell population that does not express antigen-specific recognition receptors 
like T- and B cells, but recognizes e.g. virus-infected cells that express less or no HLA-class I molecules. 
Natural killer (NK) cells are important in controlling viral infections and recognition of mutated (tumor) 
cells. 
 
Experimental autoimmune encephalitis (EAE): An animal model of multiple sclerosis that is initiated in 
animals by injecting myelin proteins or peptides to raise autoreactive T cells, or by the transfer of 
autoreactive T cells into naive recipients. 
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Figure	  2	  
Inﬂammatory	  neurodegenera2on.	  Release	  of	  pro-­‐inﬂammatory	  and	  cytotoxic	  molecules,	  
as	  well	  as	  cell	  contact	  dependent	  mechanisms	  of	  T-­‐cell	  mediated	  damage,	  may	  directly	  or	  
indirectly,	  by	  media<ng	  microglia/macrophage	  ac<va<on	  and	  oligodendrocyte	  injury,	  give	  
rise	   to	   death	   of	   neuronal	   cell	   body	   and	   nuclei	   (	   blue	   arrow	   indica<ng	   morphology	  
altera<on	   of	   the	   characteris<c	   picno<c	   nuclei),	   dendrites	   shrinkage	   and	   axonal	  
degenera<on	   in	   the	   cerebral	   cortex.	   This	   could	   in	   turn	   lead	   to	   dysfunc<on	   of	   the	  
downstream	  neuronal	  network	  (anterograde	  transynap<c	  degenera<on).	  
Non-­‐inﬂammatory	   neurodegenera2on.	   Retrograde	   degenera<on	   could	   impair	   neuronal	  
func<ons	  through	  retrograde	  damage	  propaga<ng	  backwards	  and	  leading	  to	  cell	  death	  of	  
cor<cal	  neurons	  whose	  axons	  have	  been	   impaired	   in	  white	  maDer	   lesions	  and	  along	   the	  
cor<cospinal	  tract.	  Injury	  at	  the	  terminal	  endings	  could	  spreads	  back	  towards	  the	  cell	  body	  
and	   lead	   to	   neuronal	   dying-­‐back.	   Finally,	   even	   in	   these	   cases	   ac<va<on	   of	   microglia/
macrophage	  indeed	  contribute	  to	  the	  exacerba<on	  of	  the	  damage.	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